

SPANISH HOSTING OFFERS - IF 2019

EURAXESS

TITLE

Marie Curie Post Doc position in Instituto de Investigación Biomédica de Málaga (IBIMA) :
Expression of Interest for Hosting a Marie Curie Fellowship

HOSTING SUMMARY

The group “Neuropsychopharmacology” leading by Dr./Prof Juan Suárez at the Instituto de Investigación Biomédica de Málaga (IBIMA) in Málaga (Spain) is interested in hosting a Marie Curie Fellowship. **Two projects are offered to host Marie Skłodowska-Curie** candidates to be supervised by Dr/ Prof Juan Suárez:

Dr. / Prof **Juan Suárez** has been working in **Neuropsychopharmacology of Metabolic Disorders** (<http://dwww.ibima.eu/investigador/suarez-perez-juan/>). The group has gained experience in the discovery and development of new drugs for the treatment of physio-pathologies and altered behavior of prevalent disorders, especially in the field of obesity, diabetes, Alzheimer, depression, drug addiction. The group has been working on pharmacotherapies of metabolic disorders since its establishment in 2006 and has generated 3 patents related to the field. The team dominates all technical areas of the present proposal, including translational studies from animal models, including the evaluation of animal physiology, to human high-prevalent diseases, and the analysis of molecular and biological systems, which guarantees the achievement of the aims set.

HOSTING DETAILS

Description of the center: The Biomedical Research Institute of Málaga, IBIMA, is a space for multidisciplinary biomedical research that gather the resources, skills and expertise of the main public University Hospitals, Primary Care Centers and the University of Málaga to constitute a powerful combine (www.ibima.eu/en).

IBIMA fosters translational research to accelerate the transference of the scientific breakthroughs into the prevention, diagnosis and treatment of Health Care.

IBIMA has been accredited as a Health Research Institute since January 15th 2015 by the National Health Institute Carlos III, on the basis of the Spanish Royal Decree 339/2004 of February 27th. It has a workforce of 853 people, of which 705 are researchers (56% of them having healthcare activity), 114 are technicians and 34 are managers, clustered in 44 consolidated, 4 emergent and 7 associated groups.

The Málaga Health Research Institute (IBIMA) performs its research activities within the scope of the Andalusian Health System (SAS). The SAS is an autonomous body attached to the Ministry of Health of the Government of Andalusia, in the South of Spain. Its mission is to provide public, quality health care to the citizens of Andalusia seeking efficiency and optimum use of resources. At Málaga province, the

SAS provides care to a population of 1.600.000 habitants coordinating the services of 2 University Hospitals and 48 Primary Care Centers in the city of Málaga together with those located throughout the rural territory of the province (4 Hospitals and 107 Primary Care Centers).

The IBIMA Strategic Plan_2018-2022 defines the evolution of the Institute taking into account the, European, national and regional research policies, welcoming the collaboration with private entities and analyzing the province health indicators to establish the course of actions to become the scientific and technological reference for the citizens of Málaga and of the international community.

The backbone of the IBIMA organization has been the prioritization of the lines of research pursuing the greatest impact on the health of the citizens of the Málaga province. The Institute is structured around 4 Priority and 2 transversal Research Areas, where the Research Groups, the Common Research Facilities and the Research Support Units are coordinated for the execution and the management of the research. The IBIMA Research areas are:

- 1 Cardiovascular disease, obesity and diabetes. Environmental determinants and lifestyle
- 2 Oncology and Hematology
- 3 Neurosciences, Chronicity, Aging and Health in vulnerable populations
4. Autoimmune, infectious diseases, inflammation and allergy.

Trasnversal 1. IBIMA Rare: Rare diseases

Transversal 2. IBIMA Tech: Technology Area in Health and Innovation

IBIMA Common Research Facilities (ECAI) are:

- | | |
|---------------------------|---|
| 1. Clinical studies | 6. Microscopy |
| 2. Biobank | 7. Cellular Biology (cytometry y cell cultures) |
| 3. Bioinformatics | 8. Cell production and GMP rooms |
| 4. Animal experimentation | 9. Proteomics |
| 5. Genomics | 10. Methodological and statistical advice |

IBIMA Research Support Units (UAI) are:

1. Quality, monitoring and evaluation
2. Project management
3. International Projects
4. Innovation and technology transfer

In July 2017, the European Commission awarded IBIMA_FIMABIS the HRS4R Seal in recognition of the commitment acquired in implementing the principles of the "European Charter of Researcher and Code of Conduct in the Recruitment of Researchers "through its HRS4R strategy Implementation Plan

IBIMA defines in its Training Plan 2018_2022 the aims and objectives regarding the training of IBIMA staff providing seminars, courses and events designed to foster high-quality scientific and technical training. IBIMA collaborates with the Málaga University Post-Grade Doctoral Life Science Programs and Masters.

Regarding the research funding managing, justification and auditing FIMABIS provides IBIMA with management resources and services that are independent of the governing structures of IBIMA's partners that conforms the Institute, the Andalusian Health System (SAS) and the University of Málaga This allows an efficient economic and administrative management that complies with the national, regional and international governmental-public and private funding agencies normative.

Description of the group:

Name: **Juan Suárez Pérez**, PhD in NeuroBiology
Role: Principal Investigator

Name: Fernando Rodríguez de Fonseca, MD
Role: Co-principal investigator

Name: Fermín Mayoral Cleries, MD
Role: Clinic collaborator

Name: Juan Jesús Ruíz Ruíz, MD
Role: Clinic Investigator

Name: Elena Baixeras Llano, PhD in Molecular Biology
Role: Senior Investigator

Name: Francisco Alén Fariñas, PhD in Psychology
Role: Junior Investigator

Name: Juan Decara del Olmo, PhD in Biochemistry
Role: Junior Investigator

Name: Nuria García Marchena, PhD in Psychology
Role: Junior Investigator

Name: Antonio Jesús López Gambero
Role: PhD Student (Biochemistry)

Name: Antonio Vargas Fuentes
Role: Lab technician

Description of the project/projects:

- Project 1 Objective: **Study of newly identified factors of the GH/IGF system: analysis of the molecular mechanisms regulating growth and metabolism by PAPP-A2 and development of potential novel therapies.**

This evolutionary project of childhood growth aims to establish the genetic and metabolic bases in experimental models with specific genetic alterations and the evaluation of possible treatments (IBIMA, Regional University Hospital of Malaga), as well as the subsequent therapeutic follow-up of a large infantile cohort performed in the Pediatric Endocrinology Service of the Hospital Infantil Universitario Niño Jesús de Madrid led by Dr. Jesús Argente.

- Project 2 Objective: **Alcohol Use Disorders and Cannabis consumption as risk factors for neurodegenerative disorders: identification of circulating biomarkers related to depression, dementia and stroke.**

This study aims to establish the neurobiological and behavioral bases by analyzing a cohort of alcoholics with prolonged consumption from childhood (collaboration with the Psychiatry Service of the Hospital Universitario 12 de Octubre in Madrid led by Gabriel Rubio and with the Provincial Centers of Drug Abuse in Malaga led by Juan Jesús Ruíz), as well as the development of possible treatments using specific experimental models with cognitive impairment due to abusive consumption of alcohol and Cannabis (UGC Mental Health, HRU Málaga).

Description Principal Investigator (*education, research experience, publications, projects, [ORCID ID](#), Researcher ID or other, etc.*)

The PI (<http://dwww.ibima.eu/investigador/suarez-perez-juan/>) has participated and participates in international consortiums in the area of the present project such as REPROBESITY (European Commission; FP7-Health-2007-B) and FATZHEIMER (European Commission; EULACH16/T01-0131). The PI has also obtained national funding in the area of the present project (PI16/01374, CP12/03109). Our group is recognized by the Andalucía Regional Government (PAIDI CTS-433), coordinate the Spanish Network of Addictive Disorders (RETIC-RTA) and is a founder member of the Spanish Network of Drug Discovery (REDEFAR), both affiliated with the National Institute of Health

(ISCI). The group has been working on pharmacotherapies of metabolic disorders since its establishment in 2006 and has generated 3 patents related to the field. The team dominates all technical areas of the present proposal, including studies in animal models, the evaluation of animal physiology, and the analysis of molecular and biological systems, which guarantees the achievement of the aims set. The group has made notable scientific contributions in the last 20 years reflected in more than 100 scientific publications. The PI leads half of these reports (first, last and/or corresponding author), which were published in the field of Endocrinology (Pediatric Obesity, Diabetology, Diabetes, Obesity and Metabolism), Physiology (Acta Physiologica), Pharmacology (British Journal of Pharmacology, European Neuropsychopharmacology, Neuropharmacology, International J of Neuropsychopharmacology), Substances of Abuse (Addiction Biology), Neurosciences (Journal of Comparative Neurology, Hippocampus, Frontiers in Cellular Neuroscience) and Pathology (Disease Models & Mechanisms), most of them in Q1/D1. Currently, the PI has more than 1,919 citations, 12,309 reads and a H index of 26 (WOS and Scopus). The PI has supervised several contracts from ISCI (Sara Borrell, PFIS, i-PFIS). The PI has supervised 4 dissertations of PhD students, 4 MSc projects and 2 BS projects (last 8 years).

ORCID: <https://orcid.org/0000-0001-5254-9802>

Research Gate: https://www.researchgate.net/profile/Juan_Suarez27

REDEFAR (nodo 4): <https://www.redefar.com/areas-y-nodos/#1520768315796-af201294-bf32>

SEIC: <http://www.seic.es/grupos-investigacion/neuropsicofarmacologia-los-trastornos-adictivos-metabolicos>

Supervisor Publications (last 10 publications)

1: Rivera P, et al. Perinatal free-choice of a high-calorie low-protein diet affects leptin signaling through IRS1 and AMPK dephosphorylation in the hypothalamus of female rat offspring in adulthood. *Acta Physiol (Oxf)*. 2018 Dec 27:e13244. **2:** Rivera P, et al. Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum. *Neuropharmacology*. 2019 Mar 1;146:184-197. **3:** Sampedro-Piquero P, et al. Neuroplastic and cognitive impairment in substance use disorders: a therapeutic potential of cognitive stimulation. *Neurosci Biobehav Rev*. 2018 Nov 24. **4:** Moreno M, et al. Cannabinoid dependence induces sustained changes in GABA release in the globus pallidus without affecting dopamine release in the dorsal striatum: A dual microdialysis probe study. *Addict Biol*. 2018 Nov;23(6):1251-1261. **5:** Rivera P, et al. A novel approach to childhood obesity: circulating chemokines and growth factors as biomarkers of insulin resistance. *Pediatr Obes*. 2018 Oct 22. **6:** Silva-Peña D, et al. Alcohol-induced cognitive deficits are associated with decreased circulating levels of the neurotrophin BDNF in humans and rats. *Addict Biol*. 2018 Sep 12. **7:** Alen F, et al. PPAR α /CB1 receptor dual ligands as a novel therapy for alcohol use disorder: Evaluation of a novel oleic acid conjugate in preclinical rat models. *Biochem Pharmacol*. 2018 Nov;157:235-243. **8:** Rivera P, et al. Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure. *Biochem Pharmacol*. 2018 Nov;157:244-257. **9:** Decara J, et al. The adiponectin promoter activator NP-1 induces high levels of circulating TNF α and weight loss in obese (fa/fa) Zucker rats. *Sci Rep*. 2018 Jun 29;8(1):9858. **10:** Decara J, et al. Cooperative role of the glucagon-like peptide-1 receptor and β 3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats. *Acta Physiol (Oxf)*. 2018 Apr;222(4):e13008.

>> Publications= 68 (2012-2019) H Index=26 (WOS and Scopus)

Grants=2 (active)

- PI16/01374, Early onset severe childhood obesity: Metabolic, hormonal, genetic, genomic, metabolomic and microbiotic basis Instituto de Salud Carlos III. Ministerio de Economía y

Competitividad (ISCIII).. Juan Suárez Pérez. (Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)). 126.747,5 €. PI

- PNSD2015/047, Interacción del consumo abusivo de alcohol y cannabis en neurogénesis durante la adolescencia: prevención del deterioro cognitivo Delegación del Gobierno para el Plan Nacional Sobre Drogas. Otros Programas del Plan Nacional I+D, Ministerio de Ciencia y Tecnología. Juan Suárez Pérez. (Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)). 72.723 €. PI
- High fat diet, microbiota and neuroinflammation in the progression of Alzheimer disease (FATZHEIMER) European Commission - DG Research & Innovation - 7th Framework Programme. Juan Suarez Perez. (Fundacion Publica Andaluza para la Investigación de Malaga en Biomedicina y Salud (FIMABIS)). 584.481 €. Collaborator

Patents=2

- Rodríguez-De Fonseca F; Rivera-González P; Juan Suárez Pérez; Juan Ballesteros Nobell; Carlos Diéguez González; Rubén Nogueiras Pozo; Giovanni Marsicano; Uberto Pagotto; Beat Lutz. PCT/ES2012/070276. Combined therapies based on NAEs-derived compounds for the treatment of metabolic diseases. España. 24/10/2012. FIMABIS. VIVIA BIOTECH SL.
- Fernando Rodríguez de Fonseca; Juan Suárez Pérez; Miguel Romero Cuevas; Emilio Fernández Espejo; Páez-Prósper J. A.; Goya-Laza, María Pilar. P201130486. Sulphamide-derived compounds as neuroprotectors España. 30/03/2011. FIMABIS.

Supervisor International collaborations:

- 2 Consortiums
REPROBESITY (European Commission; FP7-Health-2007-B)
FATZHEIMER (European Commission; EULACH16/T01-0131)
- 2 Networks
Spanish Network of Addictive Disorders (RETIC-RTA, <http://www.redrta.es/>)
Spanish Network of Drug Discovery (REDEFAR, <https://www.redefar.com/>)

Supervisor most relevant research projects grants:

- PI16/01374, Early onset severe childhood obesity: Metabolic, hormonal, genetic, genomic, metabolomic and microbiotic basis Instituto de Salud Carlos III. Ministerio de Economía y Competitividad (ISCIII).. Juan Suárez Pérez. (Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)). 126.747,5 €. PI
- PNSD2015/047, Interacción del consumo abusivo de alcohol y cannabis en neurogénesis durante la adolescencia: prevención del deterioro cognitivo Delegación del Gobierno para el Plan Nacional Sobre Drogas. Otros Programas del Plan Nacional I+D, Ministerio de Ciencia y Tecnología. Juan Suárez Pérez. (Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)). 72.723 €. PI
- CP12/03109, Thermogenic induction by combined therapies based on acylethanolamine-derived compounds: a new approach to treat obesity Instituto de Salud Carlos III. Ministerio de Economía y Competitividad (ISCIII). (Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)). 151.875 €. PI.

More information:

- Number of positions available: 1
- Type of contract: Senior Researcher
- Status: Supervisor
- Working hours (hour per week or free text): 40 hours/week
- State / province: Spain
- City: Málaga
- Postal code: 29010

- Street: Carlos Haya 82
- Organisation: Instituto de Investigación Biomédica de Málaga (IBIMA)
- Faculty / department: Neuroscience
- Country: Spain
- City: Málaga
- State/province: Spain
- Website: <http://www.ibima.eu/>
- Phone mobile phone: +34 952614012

APPLICATION DETAILS

- Envisaged job starting date: 01/01/2020
- Application deadline: 11/09/2019
- How to apply:
- Application e-mail : juan.suarez@ibima.eu

REQUIRED EDUCATION LEVEL

- Required education level 1: Ph.D., M.D., or equivalent.
- Degree: Biology, Biochemistry, Biotechnology, Psychiatry, Medicine, Veterinary
- Degree field:

REQUIRED EXPERIENCE LEVEL

- Main research field: Physiology
- Sub research field: Molecular Biology
- Years of research experience: 4

REQUIRED LANGUAGES

- Language: english
- Language level: CEFR equivalent to B2

ADDITIONAL REQUIREMENTS

- Skills: Animal models, animal behavior, statistical software
- Specific requirements:

At the deadline for the submission of proposals (**September, 11th 2019**), researchers:

MSCA-IF-2019

Expressions of Interest for hosting MSCA fellows



- shall be in possession of a doctoral degree or have at least four years of full-time equivalent research experience.
- must not have resided or carried out their main activities in the country of Spain for more than 12 months in the 3 years immediately prior to the abovementioned deadline.